<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467961</url>
  </required_header>
  <id_info>
    <org_study_id>070136</org_study_id>
    <secondary_id>07-H-0136</secondary_id>
    <nct_id>NCT00467961</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation for Patients With Cancers of the Blood</brief_title>
  <official_title>Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will try to improve the safety and effectiveness of stem cell transplant
      procedures in patients with cancers of the blood. It will use a special machine to separate
      immune cells (T cells) from the blood of both the donor and the patient and will use
      photodepletion, a laboratory procedure that selectively kills cancer cells exposed to light.
      These special procedures may reduce the risk of graft-versus-host-disease (GVHD), a serious
      complication of stem cell transplants in which the donor's immune cells destroy the patient's
      healthy tissues, and at the same time may permit a greater graft-versus-leukemia effect, in
      which the donated cells fight any residual tumor cells that might remain in the body.

      Patients between 18 and 75 years of age with a life-threatening disease of the bone marrow
      (acute or chronic leukemia, myelodysplastic syndrome, or myeloproliferative syndrome) may be
      eligible for this study. Candidates must have a family member who is a suitable tissue match.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral blood stem cell transplant research carried out by the NHLBI BMT Unit focus on
      approaches in transplant techniques designed to decrease graft versus host disease (GVHD),
      increase the graft-versus-leukemia (GVL) effect, and/or reduce the risk for post-transplant
      graft rejection or disease relapse.

      Ex vivo selective depletion of alloreacting T cells, hereafter referred as selective
      depletion (SD), represents a translational strategy aiming to reduce severe GVHD whilst
      preserving GVL. We found that selectively depleted transplants are safe to administer and
      associated with less severe acute GVHD. This protocol is designed to evaluate the safety and
      efficacy of photodepletion (PD) as an improved selective depletion procedure in the
      HLA-matched peripheral blood stem cell transplant setting and to determine whether
      post-transplant immunosuppression with cyclosporine is necessary to prevent severe GVHD after
      a photodepleted transplant.

      The protocol will accrue subjects ages 18-75 who are diagnosed with a hematological
      malignancy where allogeneic stem cell transplantation from an HLA-matched sibling would be
      normally indicated. Diagnostic categories will include acute and chronic leukemias,
      myelodysplastic syndromes, B-cell lymphomas, multiple myeloma, and myeloproliferative
      syndromes.

      Participants have a central intravenous (IV) line placed into a large vein. The tube is used
      for giving the donated stem cells and antibiotics and other medicines, for transfusions of
      red blood cells and platelets, and for collecting blood samples. Treatment starts with a
      conditioning regimen of chemotherapy (fludarabine and cyclophosphamide) and total body
      irradiation to suppress immunity and prevent rejection of the donated stem cells. The day
      after chemotherapy ends, the stem cells are given through the central line. This is followed
      by transfusion of the donor's immune cells, which have been treated to remove cells that
      could cause severe GVHD. Also to minimize the risk of GVHD, patients are given cyclosporine.
      Not all participants receive the same amount of this drug; in order to determine how much
      immunosuppression is needed to protect against severe GVHD, the length of treatment with
      cyclosporine varies among patients, depending on when they entered the study and how well
      preceding patients did.

      The average hospital stay for stem cell transplantation is 3 to 4 weeks. Patients return for
      frequent follow-up visits for the first 2 to 4 months after transplantation. The patient's
      referring physician is asked to send results of any laboratory testing to the NIH researchers
      at least every 3 months for the first 3 years and annually thereafter. Patient follow-up
      visits are scheduled at NIH at 1, 2, and 3 years after transplantation. After 3 years,
      participants are offered the opportunity to enroll in NHLBI's long-term evaluation and
      follow-up care protocol.

      Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine
      and total body irradiation, followed by an infusion of a stem cell product prepared using the
      Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been
      selectively depleted using the photodepletion approach (Kiadis Pharma). Older subjects will
      receive a lower dose of irradiation to reduce the regimen intensity.

      To determine appropriate level of post transplant immunosuppression, we will utilize a three
      sequential de-escalation stage design involving 17 subjects per cohort (minimum 17, maximum
      51 total evaluable subjects in study). Stopping rules for non-relapse mortality in each
      cohort will determine whether to continue to the next stage; to continue accumulating
      subjects at the same level; or to stop the protocol.

      Cohort 1: Low dose cyclosporine until day 90 then dose tapered to stop within 2 weeks.

      Cohort 2: If no severe GVHD is encountered in Cohort 1, the cyclosporine withdrawal will
      begin on day 45.

      Cohort 3: If no severe GVHD is encountered in Cohort 2, cyclosporine will not be used in the
      post-transplant period.

      Primary endpoints will be the incidence of acute grade III/IV GVHD at day 90. Secondary
      endpoints will be standard transplant outcome variables: toxicity, non relapse mortality and
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling Transplantation Followed by Low-dose or no Immunosuppression.</measure>
    <time_frame>Day 90</time_frame>
    <description>Patients will receive a selectively photodepleted lymphocyte product which will be delivered together with the T cell depleted stem cell product on the day of transplantation. Subjects will receive a conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34-selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, a three sequential de-escalation stage design for timing of cyclosporine will be utilized. To determine if selective T cell depletion using the photodepletion procedure can substantially reduce the number of severe acute GVHD (grade III/IV) after transplantation followed by low-dose or no immunosuppression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objectives Include Determining the Rate od Standard Transplant Outcome Variables: Toxicity, Relapse, Graft Rejection, Disease Free Survival.</measure>
    <time_frame>3 years maximum</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>CML (Chronic Myelogenous Leukemia)</condition>
  <condition>CLL (Chronic Lymphocytic Leukemia)</condition>
  <condition>AML (Acute Myelogenous Leukemia)</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>MDS (Myelodysplastic Syndrome)</condition>
  <arm_group>
    <arm_group_label>Miltenyi system transplant recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Miltenyi system</intervention_name>
    <description>Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.</description>
    <arm_group_label>Miltenyi system transplant recipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Recipient Criteria:

          -  Diagnosed with one of the following hematological conditions:

          -  Chronic myelogenous leukemia (CML): chronic phase who have failed treatment with
             imatinib, have intolerance to imatinib, or who did not receive imatinib at therapeutic
             doses within the first 12 months from diagnosis; accelerated phase or blast
             transformation.

          -  Acute B-lymphoblastic leukemia (B-ALL): any of these categories: B-ALL in first
             remission with high-risk features (presenting leukocyte count greater than 100,000/cu
             mm, Karyotypes t9; 22, t4, t19, t11, biphenotypic leukemia), all second or subsequent
             remissions, primary induction failure, partially responding or untreated relapse.

          -  Acute myelogenous leukemia (AML): AML in first remission - except AML with good risk
             karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), AML t (8; 21). All AML in second or
             subsequent remission, primary induction failure and resistant relapse.

          -  Myelodysplastic syndromes (MDS): any of these categories - refractory anemia with
             transfusion dependence, refractory anemia with excess of blasts, transformation to
             acute leukemia, chronic myelomonocytic leukemia, atypical MDS/myeloproliferative
             syndromes.

          -  Myeloproliferative disorders including atypical (Ph negative) chronic myeloid and
             neutrophilic leukemias, progressing myelofibrosis, and polycythemia vera, essential
             thrombocythemia in transformation to acute leukemia or with progressive transfusion
             requirements or pancytopenia.

          -  Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky
             progressive disease or with thrombocytopenia (less than or equal to 100,000 /microl)
             or anemia (less than or equal to 10g/dl) not due to recent chemotherapy.

          -  Non-Hodgkin's lymphoma including Mantle cell lymphoma relapsing or refractory to
             standard of care treatments.

          -  Multiple myeloma, Waldenstroms macroglobulinemia, unresponsive or relapsed following
             standard of care treatments.

          -  Ages 18-75 years inclusive.

          -  HLA identical (6/6) related donor.

          -  Ability to comprehend the investigational nature of the study and provide informed
             consent.

        Donor Criteria:

          -  Related HLA identical (6/6) with recipient.

          -  Weight greater than or equal to 18 kg.

          -  Age greater than or equal to 2 or less than or equal to 80 years old.

          -  For adults: Ability to comprehend the investigational nature of the study and provide
             informed consent. For minors: Written informed consent from one parent or guardian and
             informed assent: The process will be explained to the minor on a level of complexity
             appropriate for their age and ability to comprehend.

        EXCLUSION CRITERIA:

        Recipient Criteria (any of the following):

          -  Malignant cells expressing a T cell phenotype (in particular T-ALL and T cell NHL).

          -  DLCO less than 65 percent predicted.

          -  Left ventricular ejection fraction less than 40 percent (evaluated by ECHO) or less
             than 30 percent (evaluated by MUGA).

          -  AST/SGOT greater than 10 times ULN (CTCAE grade IV v3.0).

          -  Bilirubin greater than 5 times ULN (CTCAE grade IV v3.0).

          -  Creatinine greater than 4.5 times ULN (CTCAE grade IV v 3.0).

          -  HIV positive (Recipients who are positive for hepatitis B (HBV), hepatitis C (HCV) or
             human T-cell lymphotropic virus (HTLV-1/II) are not excluded from participation).

          -  Positive pregnancy test for women of childbearing age.

          -  Prior allogeneic stem cell transplantation.

          -  Estimated probability of surviving less than three months.

          -  Major anticipated illness or organ failure incompatible with survival from transplant.

          -  Severe psychiatric illness or mental deficiency sufficiently severe as to make
             compliance with the transplant treatment unlikely and informed consent impossible.

        Donor Criteria (any of the following):

          -  Pregnant or lactating.

          -  Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts,
             history of stroke, uncontrolled hypertension).

          -  Sickling hemoglobinopathies including HbSS, HbAS, HbSC.

          -  HIV positive Donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or human
             T-cell lymphotropic virus (HTLV-I/II) will be used at the discretion of the
             investigator following counseling and approval from the recipient.

          -  Severe psychiatric illness or mental deficiency sufficiently severe as to make
             compliance with the donation of stem cells unlikely and informed consent impossible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minocher M Battiwalla, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2007-H-0136.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001 May 17;411(6835):385-9. Review.</citation>
    <PMID>11357147</PMID>
  </reference>
  <reference>
    <citation>Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15;102(6):2292-9. Epub 2003 May 22. Erratum in: Blood. 2004 Sep 15;104(6):1605.</citation>
    <PMID>12763937</PMID>
  </reference>
  <reference>
    <citation>Andr√©-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G, Vilmer E, Fischer A, Cavazzana-Calvo M. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002 Jul 13;360(9327):130-7.</citation>
    <PMID>12126823</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2007</study_first_submitted>
  <study_first_submitted_qc>April 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2007</study_first_posted>
  <results_first_submitted>December 22, 2014</results_first_submitted>
  <results_first_submitted_qc>December 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2015</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Minoo Battiwalla, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CML (Chronic Myelogenous Leukemia)</keyword>
  <keyword>CLL (Chronic Lymphocytic Leukemia)</keyword>
  <keyword>AML (Acute Myelogenous Leukemia)</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Acute B-Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Selective T Cell Depletion Transplant Recipients</title>
          <description>Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, a three sequential de-escalation stage design for timing of cyclosporine will be utilized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Technical Failures</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Selective T Cell Depletion Transplant Recipients</title>
          <description>Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, a three sequential de-escalation stage design for timing of cyclosporine will be utilized.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling Transplantation Followed by Low-dose or no Immunosuppression.</title>
        <description>Patients will receive a selectively photodepleted lymphocyte product which will be delivered together with the T cell depleted stem cell product on the day of transplantation. Subjects will receive a conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34-selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, a three sequential de-escalation stage design for timing of cyclosporine will be utilized. To determine if selective T cell depletion using the photodepletion procedure can substantially reduce the number of severe acute GVHD (grade III/IV) after transplantation followed by low-dose or no immunosuppression.</description>
        <time_frame>Day 90</time_frame>
        <population>The study accrued 31 transplant recipents and 30 donors. Of the 31 transplant recipients, there were 24 evaluable recipients. Seven of the 24 recipients did not receive transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Selective T Cell Depletion Transplant Recipients</title>
            <description>Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach (Kiadis Pharma). Older subjects will receive a lower dose of irradiation to reduce the regimen intensity.
To determine appropriate level of post transplant immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling Transplantation Followed by Low-dose or no Immunosuppression.</title>
          <description>Patients will receive a selectively photodepleted lymphocyte product which will be delivered together with the T cell depleted stem cell product on the day of transplantation. Subjects will receive a conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34-selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, a three sequential de-escalation stage design for timing of cyclosporine will be utilized. To determine if selective T cell depletion using the photodepletion procedure can substantially reduce the number of severe acute GVHD (grade III/IV) after transplantation followed by low-dose or no immunosuppression.</description>
          <population>The study accrued 31 transplant recipents and 30 donors. Of the 31 transplant recipients, there were 24 evaluable recipients. Seven of the 24 recipients did not receive transplantation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects affected by Acute Grade III/ IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects unaffected by Acute Grade III/ IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Objectives Include Determining the Rate od Standard Transplant Outcome Variables: Toxicity, Relapse, Graft Rejection, Disease Free Survival.</title>
        <time_frame>3 years maximum</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Selective T Cell Depletion Transplant Recipients</title>
          <description>Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. To determine appropriate level of post transplant immunosuppression, a three sequential de-escalation stage design for timing of cyclosporine will be utilized.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression/ Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Disease relapse</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GVHD/ infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GVHD/ gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GVHD/ pulmonary</sub_title>
                <description>interstitial pneumonitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GVHD/ cytomegalovirus reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal absolute nuetrophil count</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection with cytomegalovirus reactivation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection with neutropenic fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection cytomegalovirus gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>pulmonary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>renal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>multiple opportunistic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adbdominal mantle cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD/ neurology</sub_title>
                <description>Seizures</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Minocher Battiwalla, MD</name_or_title>
      <organization>NIH NHLBI</organization>
      <phone>301-827-0939</phone>
      <email>minoo.battiwalla@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

